Ascendia Pharmaceutical Solutions Founder and CEO Jim Huang is proud to announce the expansion of the CDMO’s business development team, reinforcing our dedication to fostering strategic partnerships in the pharmaceutical industry. This growth reflects our commitment to supporting our clients during their drug development projects, from pre-formulation to commercialization.
As part of our recent expansion, we are thrilled to welcome Rhonda Baker and Matthew Maki as business development leaders at Ascendia Pharmaceutical Solutions. These two esteemed professionals will play a crucial role in strengthening client relationships and meeting their needs by explaining and highlighting the Ascendia Difference.
Learn more about Rhonda and Matthew below.
Expert Business Development Talent
Rhonda joined our team in January 2025. She brings extensive business development experience to the team.
She began her career at Wisconsin Analytical & Research Services, which was later acquired by PPD. In the early 2000s, she excelled as a sales representative at Novartis before transitioning back to pre-clinical research and development. Throughout her career, she has held various business development roles at MDS, Azopharma, AccuBreak Pharmaceuticals, WCCT Global, Eurofins Discovery, ICON plc. Rhonda also managed her own consulting firm.
Rhonda earned a Master of Science in Homeland Security and Emergency Management from Purdue Global University in 2018. In 2023, she was awarded a Master of Business Administration with an emphasis on Business Management from Purdue Global University.
Matthew is a skilled and dedicated business development leader with over 15 years of experience in the CDMO and Contract Analytical industries. He joined Ascendia Pharmaceutical Solutions in January 2025. He
has supported small and large molecules from early-phase research to full-scale commercial manufacturing for several dosage forms.
The Ascendia Difference
Both will be working with drug development teams from pharma and biopharma companies to highlight the Ascendia Difference and how it provides benefits in bringing drugs to market more efficiently. Our scientific teams apply novel approaches to develop innovative drugs. We use our four proprietary nanotechnologies – AmorSol®, EmulSol®, LipidSol™ and NanoSol® - as part of our elegant formulation development using Generally Recognized As Safe (GRAS) materials to exceed client expectations.
We also advance drug development with state-of-the art manufacturing capabilities. Ascendia Pharmaceutical Solutions is the only North American CDMO with the NETZSCH Group DeltaVita®. We are leveraging this sophisticated Netzsch Mill technology to cater to complex pharmaceutical needs, providing scalable, high-quality solutions for drug developers.
Contact us to learn how we can become your Partner of Choice for your drug development project.